Aetna under investigation after medical director said he never looked at patient records

The California Department of Insurance is now examining Aetna’s claims denial process after a former medical director for the insurer’s Southern California operations, Jay Ken Iinuma, MD, said under oath that he never looked at a patient’s health record when deciding whether to approve a deny a claim.

Iinuma said he was following Aetna’s training to review recommendations from nurses who had read the patient’s record, rather looking at the record himself. California Insurance Commissioner Dave Jones said his office has asked Aetna to provide more information about its clinical review process.

"If the health insurer is making decisions to deny coverage without a physician actually ever reviewing medical records, that's of significant concern to me as insurance commissioner in California -- and potentially a violation of law," he told CNN.

The information came out as part of Iinuma’s deposition in a lawsuit filed against Aetna by a college student with a rare immune disorder. 23-year-old Gillen Washington has accused Aetna of “almost killing him” by denying coverage for an infusion of intravenous immunoglobulin (IVIG) when he was 19, while the insurer countered that Washington ignored their request for new blood work before authorizing the treatments.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.